Extraction optimization of medicinally important metabolites from Datura innoxia Mill.: an in vitro biological and phytochemical investigation

Fatima, Humaira; Khan, Komal; Zia, Muhammad; Ur-Rehman, Tofeeq; Mirza, Bushra; Haq, Ihsan-ul

doi:10.1186/s12906-015-0891-1

BMC Complementary Medicine and Therapies

Table 5 Cytotoxicity and Streptomyces hyphae formation inhibition potential of different solvent extracts of leaf, stem and fruit of D. innoxia. Values are presented as mean ± standard deviation of triplicate analysis

From: Extraction optimization of medicinally important metabolites from Datura innoxia Mill.: an in vitro biological and phytochemical investigation

Extracts	Brine shrimp cytotoxicity (Concentration μg/ml)		THP-1 cytotoxicity (Concentration μg/ml)		Protein kinase inhibition
	% mortality	LC₅₀	% mortality	IC₅₀	Diameter (mm ± SD)
	1000		10		Clear zone	Bald zone
Leaf
Nh	100.0 ± 0.00^a	235.44 ± 1.12	22.32 ± 2.41^c	˃10	--	7 ± 0.38
C	90.00 ± 0.49^b	199.91 ± 0.98	80.95 ± 1.77^a	5.91 ± 0.78	13 ± 0.18^b	21 ± 0.29
A	96.60 ± 0.94^b	226.67 ± 1.34	18.22 ± 1.68	˃10	7 ± 0.15	11 ± 0.47
EthA	98.30 ± 0.47	150.48 ± 1.14	23.22 ± 2.13^b	˃10	7 ± 0.33	11 ± 0.39
Eth	78.30 ± 1.25	133.26 ± 0.43	31.24 ± 2.99	˃10	11 ± 0.43	22 ± 0.47^a
EC	90.0 ± 0.94^c	154.90 ± 0.22	55.23 ± 3.22	8.9 ± 0.53	14 ± .41^b	21 ± 0.52^b
MC	81.60 ± 1.70^a	85.94 ± 0.16	52.38 ± 2.87	9.8 ± 0.15	7 ± 0.32	10 ± 0.21
EthE	86.60 ± 0.94	186.95 ± 0.17	16.33 ± 3.18	˃10	7 ± 0.62	10 ± 0.15
MEth	88.30 ± 2.36	117.69 ± 0.18	18.32 ± 4.11	˃10	12 ± 0.51	18 ± 0.41^b
E	78.30 ± 0.94^a	97.08 ± 1.35	25.34 ± 1.45^b	˃10	7 ± 0.13	9 ± 0.42
M	85.00 ± 1.25	97.06 ± 1.18	16.21 ± 2.45	˃10	6 ± 0.22^b	9 ± 0.35
D	67.00 ± 1.70	247.27 ± 0.74	12.85 ± 0.83^a	˃10	--	--
Stem
Nh	100.45 ± 0.00^a	194.95 ± 0.34	--	--	6 ± 0.44	--
C	90.50 ± 0.00^a	125.53 ± 0.22	--	--	6 ± 0.58	--
A	96.60 ± 0.94^b	155.33 ± 0.98	--	--	7 ± 0.42	13 ± 0.42^b
EthA	98.35 ± 0.58^b	153.38 ± 0.54	--	--	7 ± 0.22^a	11 ± 0.22^a
Eth	78.35 ± 0.82^b	250.00 ± 0.34	--	--	9 ± 0.35^a	18 ± 0.35^a
EC	90.45 ± 0.94	154.90 ± 0.16	--	--	6 ± 0.28	9 ± 0.28^a
MC	85.40 ± 1.25^c	97.06 ± 0.17	--	--	11 ± 0.21^a	22 ± 0.21^a
EthE	86.60 ± 0.47^b	117.69 ± 0.16	--	--	6 ± 0.45^b	8 ± 0.45
MEth	88.30 ± 0.95^b	117.69 ± 1.46	--	--	6 ± 0.27	9 ± 0.27
E	78.30 ± 0.47^a	137.29 ± 1.65	--	--	8 ± 0.33	13 ± 0.33^b
M	81.60 ± 0.82^b	85.94 ± 0.76	--	--	9 ± 0.51^b	14 ± 0.51^c
D	65.56 ± 0.82^b	250.00 ± 0.17	--	--	6 ± 0.47	8 ± 0.47
Fruit
Nh	78.30 ± 1.25^a	359.12 ± 0.18	76.19 ± 1.92^a	3.49 ± 0.17	--	10 ± 0.81^b
C	91.60 ± 1.25^a	141.68 ± 1.34	76.66 ± 2.22^a	4.52 ± 1.23	--	10 ± 0.54
A	93.30 ± 0.47^a	240.91 ± 1.56	16.23 ± 2.23	˃10	11 ± 0.23^b	18 ± 0.54^a
EthA	91.60 ± 1.25^b	114.40 ± 0.78	16.88 ± 2.23	˃10	11 ± 0.47^b	17 ± 0.22^a
Eth	93.30 ± 1.25^a	201.96 ± 0.17	10.32 ± 1.45	˃10	--	10 ± 0.22
EC	91.65 ± 1.25^a	234.92 ± 0.27	18.3 ± 2.55^b	˃10	--	10 ± 0.24
MC	85.00 ± 2.83^b	54.07 ± 0.16	18.3 ± 2.66^a	˃10	--	9 ± 0.32
EthE	98.35 ± 0.47^a	218.64 ± 0.34	61.91 ± 1.22^b	8.88 ± 1.16	8 ± 0.38^b	14 ± 0.38^a
MEth	90.00 ± 1.63^a	152.61 ± 1.14	15.62 ± 1.87	˃10	--	13 ± 0.62^b
E	90.00 ± 0.82^a	229.21 ± 1.56	18.23 ± 1.27	˃10	11 ± 0.22^a	20 ± 0.67
M	85.00 ± 1.41^b	164.39 ± 1.78	16.57 ± 3.24	˃10	7 ± 0.43^c	10 ± 0.28^a
D	65.00 ± 0.82	351.71 ± 1.76	10.34 ± 1.28	˃10	--	7 ± 0.56
DMSO	--	--	--	--	--

Initially, the samples were evaluated at single highest concentration and the samples which showed more than 50 % inhibition/significant activity were tested at lower concentrations to find their LC₅₀. Negative control: DMSO. LC₅₀ of Doxorubicin (positive control employed in the brine shrimp lethality assay) was 5.93 μg/ml. IC₅₀ of 5-Florouracil (5FU) and Vincristine (positive controls employed in anticancer assay) was 5 and 8.1 μg/ml respectively. Growth inhibition zone exhibited by surfactin (positive control in Protein kinase inhibition assay) was 20 ± 1.02 mm (bald zone)
Values (mean ± SD) are average of three samples of each plant extract, analyzed individually in triplicate (n = 1 × 3). ^a-c Means difference is highly significant, slightly significant, significant at p < 0.05

Back to article page

ISSN: 2662-7671

Contact us

Submission enquiries: bmccomplementarymedicineandtherapies@biomedcentral.com
General enquiries: ORSupport@springernature.com